Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Sample size and power considerations for ordinary least squares interrupted time series analysis: a simulation study.

Hawley S, Ali MS, Berencsi K, Judge A, Prieto-Alhambra D.

Clin Epidemiol. 2019 Feb 25;11:197-205. doi: 10.2147/CLEP.S176723. eCollection 2019.

2.

Pathophysiology-based phenotyping in type 2 diabetes: A clinical classification tool.

Stidsen JV, Henriksen JE, Olsen MH, Thomsen RW, Nielsen JS, Rungby J, Ulrichsen SP, Berencsi K, Kahlert JA, Friborg SG, Brandslund I, Nielsen AA, Christiansen JS, Sørensen HT, Olesen TB, Beck-Nielsen H.

Diabetes Metab Res Rev. 2018 Jul;34(5):e3005. doi: 10.1002/dmrr.3005. Epub 2018 Apr 26.

PMID:
29697198
3.

Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile.

Christensen DH, Nicolaisen SK, Berencsi K, Beck-Nielsen H, Rungby J, Friborg S, Brandslund I, Christiansen JS, Vaag A, Sørensen HT, Nielsen JS, Thomsen RW.

BMJ Open. 2018 Apr 7;8(4):e017273. doi: 10.1136/bmjopen-2017-017273.

4.

Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort.

Gedebjerg A, Almdal TP, Berencsi K, Rungby J, Nielsen JS, Witte DR, Friborg S, Brandslund I, Vaag A, Beck-Nielsen H, Sørensen HT, Thomsen RW.

J Diabetes Complications. 2018 Jan;32(1):34-40. doi: 10.1016/j.jdiacomp.2017.09.010. Epub 2017 Sep 19.

PMID:
29107454
5.

Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.

Jensen LO, Thayssen P, Maeng M, Ravkilde J, Krusell LR, Raungaard B, Junker A, Terkelsen CJ, Veien KT, Villadsen AB, Kaltoft A, Tilsted HH, Hansen KN, Aaroe J, Kristensen SD, Hansen HS, Jensen SE, Madsen M, Bøtker HE, Berencsi K, Lassen JF, Christiansen EH.

Circ Cardiovasc Interv. 2016 Jul;9(7). pii: e003610. doi: 10.1161/CIRCINTERVENTIONS.115.003610.

PMID:
27412869
6.

Implementation of interval walking training in patients with type 2 diabetes in Denmark: rationale, design, and baseline characteristics.

Ried-Larsen M, Thomsen RW, Berencsi K, Brinkløv CF, Brøns C, Valentiner LS, Karstoft K, Langberg H, Vaag AA, Pedersen BK, Nielsen JS.

Clin Epidemiol. 2016 Jun 8;8:201-9. doi: 10.2147/CLEP.S97303. eCollection 2016.

7.

Rates of Community-based Antibiotic Prescriptions and Hospital-treated Infections in Individuals With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study, 2004-2012.

Mor A, Berencsi K, Nielsen JS, Rungby J, Friborg S, Brandslund I, Christiansen JS, Vaag A, Beck-Nielsen H, Sørensen HT, Thomsen RW.

Clin Infect Dis. 2016 Aug 15;63(4):501-11. doi: 10.1093/cid/ciw345. Epub 2016 Jun 26.

PMID:
27353662
8.

Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.

Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, Hansen HS, Krusell L, Kaltoft A, Tilsted HH, Berencsi K, Junker A, Lassen JF; SORT OUT IV Investigators.

J Am Coll Cardiol. 2016 Feb 23;67(7):751-62. doi: 10.1016/j.jacc.2015.11.051.

9.

Association of parental history of type 2 diabetes with age, lifestyle, anthropometric factors, and clinical severity at type 2 diabetes diagnosis: results from the DD2 study.

Svensson E, Berencsi K, Sander S, Mor A, Rungby J, Nielsen JS, Friborg S, Brandslund I, Christiansen JS, Vaag A, Beck-Nielsen H, Sørensen HT, Thomsen RW.

Diabetes Metab Res Rev. 2016 Mar;32(3):308-15. doi: 10.1002/dmrr.2721. Epub 2015 Nov 6.

PMID:
26408959
10.

Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial.

Jensen LO, Thayssen P, Maeng M, Ravkilde J, Hansen HS, Jensen SE, Bøtker HE, Berencsi K, Lassen JF, Christiansen EH.

Am Heart J. 2015 Aug;170(2):210-5. doi: 10.1016/j.ahj.2015.05.009. Epub 2015 May 22.

PMID:
26299216
11.

Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW.

J Am Coll Cardiol. 2015 Jun 16;65(23):2496-507. doi: 10.1016/j.jacc.2015.04.017.

12.

Prescribing practices and clinical predictors of glucose-lowering therapy within the first year in people with newly diagnosed Type 2 diabetes.

Mor A, Berencsi K, Svensson E, Rungby J, Nielsen JS, Friborg S, Brandslund I, Christiansen JS, Vaag A, Beck-Nielsen H, Sørensen HT, Thomsen RW.

Diabet Med. 2015 Dec;32(12):1546-54. doi: 10.1111/dme.12819. Epub 2015 Jul 3.

PMID:
26032247
13.

Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort.

Svensson E, Mor A, Rungby J, Berencsi K, Nielsen JS, Stidsen JV, Friborg S, Brandslund I, Christiansen JS, Beck-Nielsen H, Sørensen HT, Thomsen RW.

BMC Endocr Disord. 2014 Aug 28;14:74. doi: 10.1186/1472-6823-14-74.

14.

Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study.

Mor A, Svensson E, Rungby J, Ulrichsen SP, Berencsi K, Nielsen JS, Stidsen JV, Friborg S, Brandslund I, Christiansen JS, Beck-Nielsen H, Sørensen HT, Thomsen RW.

Diabetes Metab Res Rev. 2014 Nov;30(8):707-15. doi: 10.1002/dmrr.2539.

PMID:
24639417
15.

Does marriage protect against hospitalization with pneumonia? A population-based case-control study.

Mor A, Ulrichsen SP, Svensson E, Berencsi K, Thomsen RW.

Clin Epidemiol. 2013 Oct 11;5:397-405. doi: 10.2147/CLEP.S50505. eCollection 2013.

16.

In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2.

Berencsi K, Rani P, Zhang T, Gross L, Mastrangelo M, Meropol NJ, Herlyn D, Somasundaram R.

J Transl Med. 2011 Mar 30;9:33. doi: 10.1186/1479-5876-9-33.

17.

Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.

Swoboda RK, Somasundaram R, Caputo L, Berencsi K, von Franzke P, Taylor DD, Marincola FM, Meropol NJ, Sigurdson E, Miller E, Herlyn D.

Int J Cancer. 2010 Sep 1;127(5):1124-30. doi: 10.1002/ijc.25133.

18.

Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.

Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D.

Cancer Biol Ther. 2006 Oct;5(10):1304-12. Epub 2006 Oct 4.

PMID:
16929176
19.

Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture.

Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D.

Cancer Immunol Immunother. 2007 Mar;56(3):359-70. Epub 2006 Jun 17.

PMID:
16783574
20.

Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D.

Eur J Immunol. 2006 Feb;36(2):457-67.

21.

CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D.

J Immunol. 2005 May 1;174(9):5856-63.

22.

Infection of U937 monocytic cells with Chlamydia pneumoniae induces extensive changes in host cell gene expression.

Virok D, Loboda A, Kari L, Nebozhyn M, Chang C, Nichols C, Endresz V, Gonczol E, Berencsi K, Showe MK, Showe LC.

J Infect Dis. 2003 Nov 1;188(9):1310-21. Epub 2003 Oct 13.

PMID:
14593587
23.

Placental transfer of naturally acquired, maternal cytomegalovirus antibodies in term and preterm neonates.

Mussi-Pinhata MM, Pinto PC, Yamamoto AY, Berencsi K, de Souza CB, Andrea M, Duarte G, Jorge SM.

J Med Virol. 2003 Feb;69(2):232-9.

PMID:
12683413
24.

Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.

Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D.

Cancer Res. 2002 Sep 15;62(18):5267-72.

25.

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.

Bernstein DI, Schleiss MR, Berencsi K, Gonczol E, Dickey M, Khoury P, Cadoz M, Meric C, Zahradnik J, Duliege AM, Plotkin S.

J Infect Dis. 2002 Mar 1;185(5):686-90. Epub 2002 Feb 6.

PMID:
11865427
26.

Chlamydia pneumoniae exacerbates aortic inflammatory foci caused by murine cytomegalovirus infection in normocholesterolemic mice.

Burian K, Berencsi K, Endresz V, Gyulai Z, Valyi-Nagy T, Valyi-Nagy I, Bakay M, Geng Y, Virok D, Kari L, Hajnal-Papp R, Trinchieri G, Gonczol E.

Clin Diagn Lab Immunol. 2001 Nov;8(6):1263-6.

27.

Optimization of DNA immunization against human cytomegalovirus.

Endrész V, Burián K, Berencsi K, Gyulai Z, Kari L, Horton H, Virok D, Méric C, Plotkin SA, Gönczöl E.

Vaccine. 2001 Jul 16;19(28-29):3972-80.

PMID:
11427273
28.

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.

Berencsi K, Gyulai Z, Gönczöl E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, Starr S, Plotkin S.

J Infect Dis. 2001 Apr 15;183(8):1171-9. Epub 2001 Mar 13.

PMID:
11262198
29.

Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis.

Burian K, Kis Z, Virok D, Endresz V, Prohaszka Z, Duba J, Berencsi K, Boda K, Horvath L, Romics L, Fust G, Gonczol E.

Circulation. 2001 Mar 20;103(11):1503-8.

PMID:
11257076
30.

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.

Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox WI, Meric C, Plotkin S, Gönczöl E, Berencsi K.

J Infect Dis. 2000 May;181(5):1537-46. Epub 2000 May 15.

PMID:
10823751
31.

Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10.

Geng Y, Shane RB, Berencsi K, Gonczol E, Zaki MH, Margolis DJ, Trinchieri G, Rook AH.

J Immunol. 2000 May 15;164(10):5522-9.

32.

Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection.

Geng Y, Berencsi K, Gyulai Z, Valyi-Nagy T, Gonczol E, Trinchieri G.

Infect Immun. 2000 Apr;68(4):2245-53.

33.

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z.

J Infect Dis. 1999 Sep;180(3):843-6.

PMID:
10438376
34.

Involvement of a p53-dependent pathway in rubella virus-induced apoptosis.

Megyeri K, Berencsi K, Halazonetis TD, Prendergast GC, Gri G, Plotkin SA, Rovera G, Gönczöl E.

Virology. 1999 Jun 20;259(1):74-84.

35.

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.

Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Méric C, Plotkin SA, Gönczöl E.

Vaccine. 1999 Jan;17(1):50-8.

PMID:
10078607
36.

Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice.

Berencsi K, Endresz V, Klurfeld D, Kari L, Kritchevsky D, Gönczöl E.

Cell Adhes Commun. 1998 Jan;5(1):39-47.

PMID:
9638340
37.

Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice.

Li W, Berencsi K, Basak S, Somasundaram R, Ricciardi RP, Gönczöl E, Zaloudik J, Linnenbach A, Maruyama H, Miniou P, Herlyn D.

J Immunol. 1997 Jul 15;159(2):763-9.

PMID:
9218593
38.
39.
40.

Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses.

Berencsi K, Uri A, Valyi-Nagy T, Valyi-Nagy I, Meignier B, Peretz FV, Rando RF, Plotkin SA, Gönczöl E.

Lab Invest. 1994 Sep;71(3):350-8.

PMID:
7933985
41.

Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

Yang Y, Nunes FA, Berencsi K, Gönczöl E, Engelhardt JF, Wilson JM.

Nat Genet. 1994 Jul;7(3):362-9.

PMID:
7522742
42.

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM.

Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407-11.

43.

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB.

Berencsi K, Rando RF, deTaisne C, Paoletti E, Plotkin SA, Gonczol E.

J Gen Virol. 1993 Nov;74 ( Pt 11):2507-12.

PMID:
8245869
44.

Immunoenhancement and suppression induced by adenovirus in chicken.

Bakay M, Béládi I, Berencsi K, Sidorova E, Agadzanyan M, Fachet J, Erdei J.

Acta Virol. 1992 May;36(3):269-76.

PMID:
1360755
45.

High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity.

Gönczöl E, deTaisne C, Hirka G, Berencsi K, Lin WC, Paoletti E, Plotkin S.

Vaccine. 1991 Sep;9(9):631-7.

PMID:
1659051
46.

Impaired interleukin 2 production by spleen cells from mice infected with human adenovirus.

Berencsi K, Bakay M, Béládi I.

Acta Virol. 1991 Aug;35(4):350-6.

PMID:
1686960
47.

Involvement of prostaglandins in immunosuppression caused by adenovirus in mice.

Berencsi K, Bakay M, Béládi I.

Acta Virol. 1987 Jan;31(1):74-7.

PMID:
2883861
49.

The role of macrophages in adenovirus-induced immunosuppression in mice.

Berencsi K, Bakay M, Béládi I.

Acta Virol. 1985 Jan;29(1):61-5.

PMID:
2859763
50.

Effect of human adenovirus type 6 on the primary immune response in mice.

Berencsi K, Bakay M, Kovács P.

Acta Virol. 1982 Sep;26(5):340-5.

PMID:
6183955

Supplemental Content

Loading ...
Support Center